Immunotherapy with ’checkpoint-inhibitors‘ has significantly improved outcomes for patients with a range of malignancies. However, significant immune-mediated toxicities of these therapies are well-described. These immune-mediated toxicities can affect virtually all organ systems and are potentially fatal. The timing of onset of the adverse effects is dependent on the organ system affected and can occur after completion of the treatment. The increasing utilisation of ‘checkpoint-inhibitors’ means that Acute Physicians are likely to see a number of immune-mediated complications presenting to the AMU.

The fundamental principles of management of immune-mediated toxicities are early recognition, supportive treatment, escalating steroid therapy (dependent on the severity of the toxicity), close liaison with Oncology and specialist organ team input. Research into the optimal strategies and pathways for the management of immune-mediated toxicity, as well as increased collaboration between Acute Physicians and Oncologists, will be necessary.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. Hodi FS, O’Day S, McDermott D et al. Improved survival with ipilumumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
2. Ansell S, Lesokhin A, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015; 372: 311-9.
3. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016; 44: 51-60.
4. Champiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27: 559-74.
5. Naidoo J, Page D, Li B et al. Toxicities of the anti-PD-1 and antiPD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375-91.
6. Buchbinder E, Desai. CTLA-4 and PD-1 pathways: Similarities, Differences and Implications of their inhibition. Am J Clin Oncol 2016; 39: 98-106.
7. U.S.D.o.H.a.H. Services. Common Terminology Criteria for Adverse Events; Version 4.0: 2009.
8. Weber J, Kahler K, Hauschild A. Management of immunemediated adverse events and kinetics of response with ipilimumab. J Clin Onc 2012; 30: 2691-7.
9. Di Giacomo A, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507.
10. Minor D, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA-4 antibody (ipilimumab) induced immunemediated colitis. Cancer Biother Radipharm 2009; 24: 321-5.
11. Eggermont A, Chiarion-Sileni V, Grob J et al. Adjuvant ipilumumab versus placebo after complete resection of high risk stage III melanoma: a randomised controlled trial. Lancet Oncol 2015; 16: 522-30.
12. Corsello S, Barnabei A, Marchetti P et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 169: 1361-75.
13. Torino F, Baranbei A, Paragliola R et al. Endocrine side effects of anti-cancer drugs: mAbs and pituitary dysfunction. Eur J Endocrinol 2015; 172: 195-204.
14. Dillard T, Yedinak C, Alumkal J et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a range of cancer subtypes. Pituitary 2010; 13: 29-38.
15. Lacouture M, Wolchok J, Yosipovitch G et al. Ipilimumab in patients with cancer and management of dermatologic adverse events. J Am Acad Dermatol 2014; 71: 161-9.
16. Nishino M, Giobbie-Hurder A, Hatabu H et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 1607-16.
17. Johnson D, Balko J, Compton M et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749-55.
18. Cooksley T, Rice T. Emergency Oncology: Development, Current Position and Future Direction in the US and UK. Support Care Cancer 2017; 25:3-7.